{
    "root": "b8f45ffa-8c1d-4428-96f2-1c57fd45810f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fenofibrate",
    "value": "20250311",
    "ingredients": [
        {
            "name": "FENOFIBRATE",
            "code": "U202363UOS"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "DIMETHICONE, UNSPECIFIED",
            "code": "92RU3N3Y1O"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        }
    ],
    "indications": "fenofibrate tablet usp peroxisome proliferator-activated receptor ( ppar ) alpha agonist indicated adjunct diet : • reduce elevated ldl-c , total-c , tg apo b , increase hdl-c adult patients primary hypercholesterolemia mixed dyslipidemia ( 1.1 ) . • treatment adult patients severe hypertriglyceridemia ( 1.2 ) . limitations : fenofibrate shown reduce coronary heart disease morbidity mortality patients type 2 diabetes mellitus ( 5.1 ) .",
    "contraindications": "• primary hypercholesterolemia mixed dyslipidemia : initial dose 160 mg daily ( 2.2 ) . • severe hypertriglyceridemia : initial dose 54 160 mg daily . maximum dose 160 mg ( 2.3 ) . • renally impaired patients : initial dose 54 mg daily ( 2.4 ) . • geriatric patients : select dose basis renal function ( 2.5 ) . • given meals ( 2.1 ) .",
    "warningsAndPrecautions": null,
    "adverseReactions": "• severe renal dysfunction , including dialysis patients ( 4 , 8.6 , 12.3 ) . • active liver disease ( 4 , 5.3 ) . • gallbladder disease ( 4 , 5.5 ) . • known hypersensitivity fenofibrate ( 4 ) . • nursing mothers ( 4 , 8.2 ) .",
    "indications_original": "Fenofibrate tablet USP is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: • To reduce elevated LDL-C, Total-C, TG and      Apo B, and to increase HDL-C in adult patients with primary      hypercholesterolemia or mixed dyslipidemia ( 1.1 ). • For treatment of adult patients with      severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ).",
    "contraindications_original": "• Primary hypercholesterolemia or mixed      dyslipidemia: Initial dose of 160 mg once daily ( 2.2 ). • Severe hypertriglyceridemia: Initial dose      of 54 to 160 mg once daily. Maximum dose is 160 mg ( 2.3 ). • Renally impaired patients: Initial dose of      54 mg once daily ( 2.4 ). • Geriatric patients: Select the dose on      the basis of renal function ( 2.5 ). • Should be given with meals ( 2.1 ).",
    "adverseReactions_original": "• Severe renal dysfunction, including dialysis patients      ( 4 , 8.6 , 12.3 ). • Active liver disease ( 4 , 5.3 ). • Gallbladder disease ( 4 , 5.5 ). • Known hypersensitivity to fenofibrate ( 4 ). • Nursing mothers ( 4 , 8.2 )."
}